Mercado mundial de la enfermedad de Chester-Erdheim: tendencias de la industria y pronóstico hasta 2029

Análisis y tamaño del mercado de la enfermedad de Erdheim Chester

Se espera que el mercado mundial de la enfermedad de Erdheim-Chester experimente un crecimiento significativo durante el período de pronóstico. La enfermedad de Erdheim-Chester se conoce como un cáncer de sangre poco común de crecimiento lento llamado neoplasia histiocítica. Conduce a la sobreproducción de células conocidas como histiocitos. La enfermedad puede ocurrir a cualquier edad, con signos y síntomas que aparecen principalmente entre los 40 y los 60 años. Las personas que padecen esta afección pueden tener dificultad para respirar, infertilidad, ojos saltones, enfermedad renal o cardíaca y convulsiones. COVID-19 también tuvo un gran impacto en el crecimiento del mercado.

Data Bridge Market Research analiza la tasa de crecimiento del mercado global de la enfermedad de Erdheim-Chester en el período de pronóstico 2022-2029. La CAGR esperada del mercado global de la enfermedad de Erdheim-Chester tiende a rondar el 7,10% en el período de pronóstico mencionado. El mercado se valoró en USD 4.6 mil millones en 2021 y crecería hasta USD 7.96 mil millones para 2029. Además de los conocimientos del mercado, como el valor de mercado, la tasa de crecimiento, los segmentos del mercado, la cobertura geográfica, los actores del mercado y el escenario del mercado, el informe de mercado curado por el equipo de Data Bridge Market Research también incluye un análisis profundo de expertos, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.

Definición de mercado

La enfermedad de Erdheim-Chester también se denomina granulomatosis lipoidea, un tipo de cáncer multisistémico poco común que se caracteriza por la secreción y el depósito excesivos de glóbulos blancos en múltiples tejidos y órganos. En la enfermedad de Erdheim-Chester, el paciente suele experimentar dolor óseo, fibrosis retroperitoneal y otros síntomas. Las personas con enfermedad de Erdheim-Chester experimentan dolor óseo, especialmente en la parte superior de los brazos y la parte inferior de las piernas, como resultado de un aumento anormal de la densidad ósea. También pueden surgir problemas hormonales como resultado del daño a la glándula pituitaria.

Alcance y segmentación del mercado de la enfermedad de Chester de Erdheim

Global Erdheim Chester Disease Market Dynamics

Drivers

• Notable Developments in terms of Market Players

Recently, some promising and innovative developments have been in the global erdheim-chester disease market. The market has observed the presence of several noticeable market players with each of the players competing for more revenue and greater reach. Research and development activities has played a critical role in the expansion of the share of the market and growing revenue for the market players. This boosts the market growth.

• Increasing Demand of Targeted Therapy

The rising demand for targeted therapy showed many advantages as it interferes with specific proteins involved in tumorigenesis focusing on specific molecular changes, which stop the growth of various types of cancers. Several significant factors influenced melanoma growth, including the fewer adverse effects of the therapy and the availability of several targeted therapeutics. This boosts the market growth.

• Increase in Erdheim-Chester Disease

Global erdheim-chester disease has occurred to almost 600-700 patients. Since there is no accepted Erdheim-Chester Disease treatment, more than half of the patients die within three years of treatment. This is projected to increase the demand for these drugs during the forecast period.

Opportunities

• Growing Healthcare Infrastructure

Researchers found that more than half of people suffering from this condition have a specific mutation in their BRAF gene. The gene delivers instructions for making a protein that further helps transmit chemical signals from outside the cell to the nucleus. The rising healthcare expenditure in several countries globally is expected to drive the demand for Erdheim-Chester disease treatment options. Thus, in return will create much opportunities for the market growth.

• Increasing Demand for Retail Pharmacies

The rise in the number of drugs for erdheim chester disease delivered throgh retail pharmacies and the increase in the number of retail pharmacies in highly developed countries create opportunities for the market growth. Additionally, patients choose retail pharmacies for purchasing drugs, as these are easily accessible.

• Higher Funding by Governments

The growing funding by government organizations in R&D activities, particularly in the U.S. and Canada is projected to drive the market. For instance, in January 2022, the National Comprehensive Cancer Network (NCCN) announced its Clinical Practice Guidelines in Oncology for histiocytic neoplasms. The goal is to provide recommendations for treating and diagnosing adults surviving with histiocytic neoplasms. The NCCN has set guidelines from all the gathered data from case reports, case series, and small retrospective studies. Thus, all these initiaves are creating much market growth opportunities as it helps spread the diasese awareness.

 Restraints/Challenges

• Unavailability of Appropriate Treatments

To treat conditions that are rare, many times all treatments are not available, especially in underdeveloped countries. Severe patients need to be treated with advanced techniques, but these are sometimes unavailable in the hospitals and clinics. Thus, it hampers the market growth.

• High Cost

The huge expenditure associated with the several treatment methods such as chemotherapy, and targeted therapy in high demand in recent years hamper the market growth. R&D activities related with the treatment of Erdheim-Chester disease involve huge cost spending. Not all companies based in developing economies can afford the amount. Thus, all these factors hamper the growth of the market.

This global erdheim chester disease market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global erdheim chester disease market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Erdheim Chester Disease Market

The pandemic has significantly affected several diagnostic methods due to several restrictions and risk exposure of comorbidity patients. A drastic reduction in treating other rare diseases was seen early in the COVID-19 pandemic, which irrationally affected the elderly, females, and certain geographic regions. However, efforts have been made by the government to contain the situation in the post-pandemic era.

Global Erdheim Chester Disease Market Scope

The global erdheim chester disease market is segmented on the basis of treatment type, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment Type

• Chemotherapy
• Targeted Therapy
• Surgery
• Others

Route of Administration

• Oral
• Parenteral
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Erdheim Chester Disease Market Regional Analysis/Insights

The global erdheim chester disease market is analysed and market size insights and trends are provided by treatment type, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global erdheim chester disease market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing a positive growth for global erdheim chester disease market throughout the forecasted period due to the increase government funding and awareness.

North America dominates the market due to the high prevalence of Erdheim-Chester disease in this region and large availability of treatment options for patient suffering of Erdheim-Chester disease supported by reimbursement policies.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Erdheim Chester Disease Market Share Analysis

El panorama competitivo del mercado global de la enfermedad de Erdheim-Chester proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, la presencia global, los sitios e instalaciones de producción, las capacidades de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, la amplitud y la variedad de productos, el dominio de las aplicaciones. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de las empresas en relación con el mercado global de la enfermedad de Erdheim-Chester.

Los actores clave que operan en el mercado global de la enfermedad de Erdheim-Chester incluyen:

• Johnson & Johnson Private Limited (Estados Unidos)
• Mylan NV (Estados Unidos)
• Industrias farmacéuticas Sun Limited (India)
• Sanofi SA (Francia)
• Bayer AG (Alemania)
• Lilly (Estados Unidos)
• GSK plc (Reino Unido)
• Novartis AG (Suiza)
• AbbVie Inc. (Estados Unidos)
• Industrias farmacéuticas Teva Ltd. (Israel)
• Sanofi (Francia)
• Hikma Pharmaceuticals PLC (Reino Unido)
• Cipla Inc. (India)
• Horizon Therapeutics plc (Dublín)
• Jubilant Pharmova Limited (India)
• Laboratorios Vintage (India)

SKU-54369